Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)

Next Previous
Trial Profile

An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Methotrexate; Methotrexate; Methotrexate
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms TRANSIT
  • Sponsors Janssen-Cilag

Most Recent Events

  • 07 Nov 2012 Quality of life outcomes presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
  • 28 Sep 2012 Results were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.
  • 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top